Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Horvath

Showing results (251-260 of 279) with videos related to

Pageof 28
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 16, 2010
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and developmentTina Bianco-Miotto, Karen Chiam, Grant Buchanan, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2022
Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statementsEdmund Chiong, Declan G Murphy, Nicholas C Buchan, et al.
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Oncoimmunology|July 30, 2016
CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesPhillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, et al.
Cancer Research|August 7, 2021
Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid CompositionLisa M Butler, Chui Yan Mah, Jelle Machiels, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1999
Advanced epithelial ovarian cancer: 1998 consensus statementsJ S Berek, K Bertelsen, A du Bois, et al.
Pageof 28

Showing results (251-260 of 279) with videos related to

Sort By:
Pageof 28
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 16, 2010
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and developmentTina Bianco-Miotto, Karen Chiam, Grant Buchanan, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2022
Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statementsEdmund Chiong, Declan G Murphy, Nicholas C Buchan, et al.
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Oncoimmunology|July 30, 2016
CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesPhillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, et al.
Cancer Research|August 7, 2021
Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid CompositionLisa M Butler, Chui Yan Mah, Jelle Machiels, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1999
Advanced epithelial ovarian cancer: 1998 consensus statementsJ S Berek, K Bertelsen, A du Bois, et al.
Pageof 28